Documenti analoghi

• A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
  di: David Kudrow, et al.
  Pubblicazione: (2025)
• Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
  di: Larry Charleston, et al.
  Pubblicazione: (2026)
• A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
  di: Chay Ngee Lim, et al.
  Pubblicazione: (2025)
• Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States
  di: Noah Rosen, et al.
  Pubblicazione: (2025)
• Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
  di: Jessica Ailani, et al.
  Pubblicazione: (2024)